Product Type: Inhibitor
CAS No.: 61413-54-5
MolecularFormula: C16H21NO3
Molecular Weight: 275,35
Source: Synthetic
Purity: >98% (TLC); NMR (Conforms)
Solubility: Soluble to 75 mM in DMSO and to 75 mM in ethanol.
Appearance: White to off-white solid.
PubChem CID: 5092
Scientific Background: Rolipram has been observed to selectively inhibit cAMP-phosphodiesterase (PDE4) by recruiting PDE4 into cytosolic aggregates that are not membrane-encapsulated. A down-stream effect of this observation is the inhibition of autophagy. Under normal conditions, autophagosomes are coated with the autophagic marker light chain 3 (LC3). LC3 binds directly to p62 protein, which shuttles protein to aggresomes, eventually leading to an autophagic event. In the absence of LC3, protein aggregates will not undergo autophagy, and will remain as cytosolic aggregates, as seen with the inhibition of PDE4 by Rolipram.
References: 1. Kato H., et al. (1995) Eur J Pharmacol. 272(1): 107-10.2. Christian F., et al. (2010) Cell Signal. 22(10): 1576-96.3. Houslay M.D., & Christian F. (2010) Autophagy. 6(8): 1198-200.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
